繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Sonnet BioTherapeutics, Sarcoma Oncology Center Collaborating to Advance Pancreatic Cancer Drug Trial

2024-08-20 00:48

12:48 PM EDT, 08/19/2024 (MT Newswires) -- Sonnet BioTherapeutics (SONN) said Monday it is collaborating with Sarcoma Oncology Center to advance the development of SON-1210, the company's proprietary bifunctional treatment combining human Interleukins IL-12 and IL-15, with chemotherapy for metastatic pancreatic cancer.

Financial details weren't disclosed.

Under the collaboration, SON-1210 is expected to enter a phase 1/2a clinical trial to evaluate its effectiveness with existing chemotherapy agents for metastatic pancreatic cancer, the company said, adding that it will supply the drug and support services for the trial.

Sonnet shares were nearly 3% higher in recent trading.

Price: 0.70, Change: +0.03, Percent Change: +5.16

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。